loading
Schlusskurs vom Vortag:
$34.02
Offen:
$34
24-Stunden-Volumen:
1.71M
Relative Volume:
1.08
Marktkapitalisierung:
$4.04B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-11.60
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
+5.77%
1M Leistung:
+14.40%
6M Leistung:
+11.47%
1J Leistung:
-27.58%
1-Tages-Spanne:
Value
$33.07
$34.49
1-Wochen-Bereich:
Value
$32.17
$35.14
52-Wochen-Spanne:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Firmenname
Avidity Biosciences Inc
Name
Telefon
858-401-7900
Name
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
391
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-07
Name
Neueste SEC-Einreichungen
Name
RNA's Discussions on Twitter

Vergleichen Sie RNA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RNA
Avidity Biosciences Inc
33.53 3.82B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Goldman Buy
2025-06-24 Eingeleitet Bernstein Outperform
2025-06-17 Eingeleitet Wolfe Research Outperform
2025-06-11 Eingeleitet Raymond James Strong Buy
2025-03-13 Eingeleitet Citigroup Buy
2025-03-12 Eingeleitet BMO Capital Markets Outperform
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2024-12-20 Eingeleitet H.C. Wainwright Buy
2024-11-26 Eingeleitet RBC Capital Mkts Outperform
2024-09-24 Eingeleitet Goldman Buy
2024-08-28 Eingeleitet Barclays Overweight
2024-05-03 Eingeleitet BofA Securities Buy
2024-03-14 Eingeleitet Cantor Fitzgerald Overweight
2023-05-22 Hochstufung Evercore ISI In-line → Outperform
2023-03-31 Herabstufung Evercore ISI Outperform → In-line
2022-07-20 Eingeleitet Chardan Capital Markets Buy
2022-07-12 Eingeleitet Raymond James Strong Buy
2021-09-07 Eingeleitet Evercore ISI Outperform
2021-06-17 Eingeleitet Needham Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-07-07 Eingeleitet Cowen Outperform
2020-07-07 Eingeleitet Credit Suisse Outperform
2020-07-07 Eingeleitet SVB Leerink Outperform
2020-07-07 Eingeleitet Wells Fargo Overweight
Alle ansehen

Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten

pulisher
12:20 PM

What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com

12:20 PM
pulisher
Jul 22, 2025

What drives Avidity Biosciences Inc. stock priceRobust financial gains - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Is Avidity Biosciences Inc. a good long term investmentTriple-digit returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Why Avidity Biosciences Inc. stock attracts strong analyst attentionCapital Doubling Tips - beatles.ru

Jul 18, 2025
pulisher
Jul 18, 2025

(RNA) On The My Stocks Page - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 14, 2025

Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive (NASDAQ:RNA) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 14, 2025

RNA News Today | Why did Avidity Biosciences stock drop today? - MarketBeat

Jul 14, 2025
pulisher
Jul 10, 2025

Goldman Sachs resumes coverage on Avidity Biosciences stock with Buy rating - Investing.com Canada

Jul 10, 2025
pulisher
Jul 09, 2025

Avidity Biosciences, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Jul 09, 2025
pulisher
Jul 09, 2025

Avidity Biosciences, Inc Rings the Opening Bell - Nasdaq

Jul 09, 2025
pulisher
Jul 07, 2025

Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces key milestones - Investing.com

Jul 07, 2025
pulisher
Jun 30, 2025

Avidity Biosciences, Inc.(NasdaqGM: RNA) added to Russell 3000E Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

(RNA) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 27, 2025
pulisher
Jun 26, 2025

Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications - TipRanks

Jun 26, 2025
pulisher
Jun 18, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

(RNA) Proactive Strategies - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter

Jun 15, 2025
pulisher
Jun 14, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia

Jun 14, 2025
pulisher
Jun 14, 2025

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 13, 2025

Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress – Company AnnouncementFT.com - Financial Times

Jun 11, 2025
pulisher
Jun 11, 2025

Avidity's Muscular Dystrophy Drug Del-brax Gets FDA Accelerated Approval Path: Key Data Coming - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Avidity Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Avidity Biosciences holds annual stockholders meeting - Investing.com

Jun 10, 2025
pulisher
Jun 10, 2025

Avidity Biosciences price target raised to $75 from $65 at Chardan - Yahoo Finance

Jun 10, 2025

Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):